Description
| - 380 komerčně dostupných monoklonálních protilátek (mAbs) proti lidským CD molekulám bylo testováno na křížovou reaktivitu na leukocytech, trombocytech a erytrocytech periferní krve psa pomocí průtokové cytometrie. Bylo nalezeno celkem 51 křížově reagujících mAbs. mAbs se specificitou pro CD9, CD29, CD42a, CD61 a CD41/CD61 vykazovaly reaktivitu s psími trombocyty a jedna mAb reagovala s erytrocytárním antigenem CD235a. S leukocyty psa reagovalo několik mAbs se specificitou pro CD11a, CD11b, CD14, CD18, CD21, CD22, CD47, CD49d, CD49e, CD56, CD62L, CD91, CD94 a CD172a. Navíc, několik mAbs vykazovalo charakter značení, který naznačuje, že psí ekvivalenty mají jinou buněčnou expresi než jaká se dala očekávat z údajů z lidské imunologie. Mezi tyto mAbs patří protilátky proti CD1a, CD35, CD44, CD45, CD75s, CD81. Výsledkem práce tedy je, že byla potvrzena křížová reaktivita některých již dříve popsaných protilátek a byly charakterizovány mAbs, které rozpoznávají dosud nedetekované CD molekuly psa. (cs)
- A panel of 380 commercially available monoclonal antibodies (mAbs) against human CD molecules was tested for cross-reactivity on canine peripheral blood leukocytes, platelets and erythrocytes by flow cytometry. This testing resulted in 51 cross-reacting mAbs. mAbs with specificity for CD9, CD29, CD42a, CD61, and CD41/CD61 showed cross-reactivity with canine platelets and one mAb with the erythrocyte antigen CD235a. Canine leukocyte-reactive mAbs included those with specificity for CD11a, CD11b, CD14, CD18, CD21, CD22, CD47, CD49d, CD49e, CD56, CD62L, CD91, CD94, and CD172a. In addition, several mAbs resulted in a staining pattern of canine cells which suggest that the canine epitope equivalents have an alternate expression pattern from that expected for humans (CD1a, CD35, CD44, CD45, CD75s, CD81). In summary, this study confirmed the reactivity of previously described crossreactive mAbs with canine cells and resulted in the characterization of mAbs recognizing so far undetectable canine CD molecules.
- A panel of 380 commercially available monoclonal antibodies (mAbs) against human CD molecules was tested for cross-reactivity on canine peripheral blood leukocytes, platelets and erythrocytes by flow cytometry. This testing resulted in 51 cross-reacting mAbs. mAbs with specificity for CD9, CD29, CD42a, CD61, and CD41/CD61 showed cross-reactivity with canine platelets and one mAb with the erythrocyte antigen CD235a. Canine leukocyte-reactive mAbs included those with specificity for CD11a, CD11b, CD14, CD18, CD21, CD22, CD47, CD49d, CD49e, CD56, CD62L, CD91, CD94, and CD172a. In addition, several mAbs resulted in a staining pattern of canine cells which suggest that the canine epitope equivalents have an alternate expression pattern from that expected for humans (CD1a, CD35, CD44, CD45, CD75s, CD81). In summary, this study confirmed the reactivity of previously described crossreactive mAbs with canine cells and resulted in the characterization of mAbs recognizing so far undetectable canine CD molecules. (en)
|